Director, Biotechnology Development and Applications Group
Dr. Paul Hatzinger is the Director of the Biotechnology Development and Applications Group at Aptim. He holds PhD from Cornell University, and has more than 20 years of experience in biodegradation, bioremediation, microbial ecology, stable isotope analysis, and groundwater microbiology. Dr. Hatzinger’s research group has been instrumental in the development and field application of new remedial approaches for several contaminants of concern to the Department of Defense, including 1,2-dibromoethane (EDB), N-nitrosodimethylamine (NDMA), perchlorate, methyl tertiary butyl ether (MTBE), and explosives (RDX, HMX, TNT). In addition to research, Dr. Hatzinger does extensive consulting on the sources, fate, and remediation of organic and inorganic pollutants.
Documenting and Enhancing In Situ Degradation of 1,2-Dibromoethane (EDB)
1,2-Dibromoethane (EDB) is a probable human carcinogen that was historically added to leaded gasoline as a scavenger to prevent the build-up of lead oxide deposits in engines, including aircraft engines. Although lead was largely removed from gasoline in the US by the end of the 1980s, studies indicate that EDB is present at thousands of past fuel spill sites above its EPA Maximum Contaminant Level (MCL) of 0.05 µg/L. Despite its apparent persistence, EDB is biodegradable under both aerobic and anaerobic conditions and subject to abiotic degradation via multiple mechanisms. During this presentation, mechanisms of EDB loss will be reviewed and a case study will be presented detailing the application of compound-specific stable isotope analysis (CSIA), microbial community analysis and bromide-chloride ratios to document EDB attenuation at a large fuel spill site. The design and implementation of a field study to stimulate the aerobic cometabolism of EDB in groundwater by applying ethane gas and oxygen will also be presented. During this study, which utilized a groundwater recirculation design, in situ EDB concentrations were reduced to < 0.02 µg/L, showing that cometabolic bioremediation can achieve the stringent MCL for this compound.
Biological Treatment of N-nitrosodimethylamine (NDMA) to Part-Per-Trillion Concentrations